Evidence map›Paper›PMID 30734287›Full record

ArticleFEBS letters2019

Methylene blue does not bypass Complex III antimycin block in mouse brain mitochondria.

Artem P Gureev, Ekaterina A Shaforostova, Vasily N Popov, Anatoly A Starkov

Open access · bronzeAbstract read
In one paragraph

Article in FEBS letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.0field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Artem P GureevDepartment of Genetics, Cytology and Bioengineering, Voronezh State University, Russia.ORCID 0000-0003-3562-5329
Ekaterina A ShaforostovaDepartment of Genetics, Cytology and Bioengineering, Voronezh State University, Russia.
Vasily N PopovDepartment of Genetics, Cytology and Bioengineering, Voronezh State University, Russia.
Anatoly A StarkovBrain and Mind Research Institute, Weill Medical College of Cornell University, New York, NY, USA.
Voronezh State University · RUCornell University · US

Funding

TRANSCRIPTIONAL RESPONSES TO MITOCHONDRIAL DYSFUNCTIONP01AG014930 · NIA · WINIFRED MASTERSON BURKE MED RES INST · PI GIBSON, GARY E · 1999 to 2020
$30.7M
NIA NIH HHS P01 AG014930
6 · The paper itself

Abstract

Methylene blue (MB) is a promising prodrug to treat mitochondrial dysfunctions that is currently being used in clinical trials for Alzheimer's disease. MB can penetrate the blood brain barrier, accumulating in brain mitochondria where it acts as a redox mediator in the electron transfer chain (ETC). Mitochondrial flavins are thought to reduce MB, which is then oxidized by cytochrome c, thereby bypassing inhibited Complex I of ETC. We found that in mouse brain mitochondria, MB fails to restore the membrane potential and respiration inhibited by antimycin. Furthermore, antimycin inhibits MB-induced H

Indexed as

AnimalsAntimycin ABlood-Brain BarrierBrainElectron TransportElectron Transport Complex IIIFemaleHydrogen PeroxideMaleMethylene BlueMiceMice, Inbred C57BLMitochondriaantimycinAntimycin AElectron Transport Complex IIIHydrogen PeroxideMethylene Blueantimycinbrain mitochondriacomplex IIIcytochrome celectron transport chainmethylene bluerotenone

Identifiers

PMID30734287
PMCPMC6433145
OpenAlexW2913052945

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.